Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Arlen

Showing results (151-160 of 171) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2010
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancerPhilip W Kantoff, Thomas J Schuetz, Brent A Blumenstein, et al.
The Journal of Urology|January 27, 2009
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablationWilliam D Figg, Maha H Hussain, James L Gulley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancerJames L Gulley, Philip M Arlen, Anne Bastian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
A phase II clinical trial of sorafenib in androgen-independent prostate cancerWilliam L Dahut, Charity Scripture, Edwin Posadas, et al.
Frontiers in Oncology|July 9, 2020
Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian CancerKristen P Zeligs, Maria Pia Morelli, Justin M David, et al.
Cancer Biology & Therapy|September 3, 2005
A phase II study of perifosine in androgen independent prostate cancerEdwin M Posadas, James Gulley, Philip M Arlen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinomaJames L Gulley, Philip M Arlen, Kwong-Yok Tsang, et al.
The Journal of Urology|August 21, 2007
Clinical safety of a viral vector based prostate cancer vaccine strategyPhilip M Arlen, Lisa Skarupa, Mary Pazdur, et al.
European Urology Oncology|October 20, 2023
Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with EnzalutamideShruti U Gandhy, Fatima H Karzai, Marijo Bilusic, et al.
JAMA Oncology|August 21, 2015
Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical TrialChristopher R Heery, Nuhad K Ibrahim, Philip M Arlen, et al.
Pageof 18

Showing results (151-160 of 171) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2010
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancerPhilip W Kantoff, Thomas J Schuetz, Brent A Blumenstein, et al.
The Journal of Urology|January 27, 2009
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablationWilliam D Figg, Maha H Hussain, James L Gulley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancerJames L Gulley, Philip M Arlen, Anne Bastian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
A phase II clinical trial of sorafenib in androgen-independent prostate cancerWilliam L Dahut, Charity Scripture, Edwin Posadas, et al.
Frontiers in Oncology|July 9, 2020
Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian CancerKristen P Zeligs, Maria Pia Morelli, Justin M David, et al.
Cancer Biology & Therapy|September 3, 2005
A phase II study of perifosine in androgen independent prostate cancerEdwin M Posadas, James Gulley, Philip M Arlen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinomaJames L Gulley, Philip M Arlen, Kwong-Yok Tsang, et al.
The Journal of Urology|August 21, 2007
Clinical safety of a viral vector based prostate cancer vaccine strategyPhilip M Arlen, Lisa Skarupa, Mary Pazdur, et al.
European Urology Oncology|October 20, 2023
Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with EnzalutamideShruti U Gandhy, Fatima H Karzai, Marijo Bilusic, et al.
JAMA Oncology|August 21, 2015
Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical TrialChristopher R Heery, Nuhad K Ibrahim, Philip M Arlen, et al.
Pageof 18